Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEY1107 plus Temozolomide in Recurrent Glioblastoma
NCT05769660Phase 1Recruiting
- Sponsor
- BeyondBio Inc.
- Start
- Nov 2022
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Avotaciclib in glioblastoma multiforme (GBM), sponsored by BeyondBio Inc. Primary endpoints: Maximum Tolerated Dose at 4 weeks and Recommended Phase II Dose at 48 weeks. Started Nov 2022; status: recruiting.
02
Drugs
Avotaciclib
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT05769660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05769660.